Create Free Account

By creating account you will get access to hot stocks & personalised emails

Tissue Repair Ltd

Healthcare AU TRP

0.27AUD
-(-%)

Last update at 2024-12-18T23:15:00Z

Day Range

0.270.27
LowHigh

52 Week Range

0.180.50
LowHigh

Fundamentals

  • Previous Close 0.27
  • Market Cap15.42M
  • Volume1540
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.87595M
  • Revenue TTM1.79M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM 0.97M
  • Diluted EPS TTM-0.07

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -4.17441M -6.83759M -0.91523M -0.50087M -0.55515M
Minority interest - - - - -
Net income -4.17441M -6.83759M -0.91523M -0.35221M -0.35719M
Selling general administrative 1.18M 1.87M 0.06M 0.07M 0.02M
Selling and marketing expenses - - - - -
Gross profit 0.00308M - - - -
Reconciled depreciation 0.00265M 0.00171M - - -
Ebit -4.77175M -6.83759M -0.48853M -0.44856M -
Ebitda -5.73768M -6.83587M - - -
Depreciation and amortization - 0.00171M - - -
Non operating income net other - - - - -
Operating income -4.77175M -6.83759M -0.55337M -0.50090M -0.55722M
Other operating expenses - 5.45M - - -
Interest expense - 0.00000M - - -
Tax provision 0.00000M 0.00000M 0.00000M -0.14865M -0.19795M
Interest income 0.60M 0.04M 0.36M 0.00004M 0.00208M
Net interest income 0.43M 0.04M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -1.42871M - -0.14865M -
Total revenue 0.00308M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses - 5.45M - - -
Cost of revenue - - - - -
Total other income expense net 1.14M -1.42871M - - -
Discontinued operations - - - - -
Net income from continuing ops -4.17441M -6.83759M - - -
Net income applicable to common shares -4.17441M -6.83759M -0.91523M -0.35221M -0.35719M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 19.39M 22.38M 25.90M 27.61M 1.33M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.20M 0.02M 0.06M 0.00500M 0.01M
Total liab 1.35M 0.50M 0.56M 0.54M 0.33M
Total stockholder equity 18.04M 21.88M 25.34M 27.07M 1.00M
Deferred long term liab - - - - -
Other current liab 0.70M 0.03M 0.36M 0.00200M -
Common stock 35.04M 35.04M 35.04M 33.06M 3.85M
Capital stock - 35.04M 35.04M 33.06M -
Retained earnings -18.94218M -14.80408M -10.62967M -6.05100M -2.87685M
Other liab - 0.00655M 0.00086M - -
Good will - - - - -
Other assets - - - - 0.00500M
Cash 16.44M 21.40M 25.46M 27.11M 1.15M
Cash and equivalents - - - - -
Total current liabilities 1.34M 0.49M 0.56M 0.54M 0.33M
Current deferred revenue - - - - -
Net debt -16.44105M - -25.45529M -27.11100M -
Short term debt - 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - 1.65M 0.93M 0.06M 0.02M
Property plant equipment - 0.00181M 0.00221M - -
Total current assets 19.39M 22.38M 25.90M 27.61M 1.32M
Long term investments - - - - -
Net tangible assets - 21.88M 25.34M 0.09M 1.00M
Short term investments - - - - -
Net receivables 2.53M 0.83M 0.05M 0.05M 0.16M
Long term debt - - 0.00000M 7.50M -
Inventory 0.21M 0.02M - 0.44M -
Accounts payable 0.64M 0.08M 0.20M 0.53M 0.33M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.94M - 0.93M 0.06M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00000M - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00343M 0.00181M 0.00221M 0.00000M -
Capital lease obligations - - - - -
Long term debt total - 0.00000M 0.00000M 7.50M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Investments -0.00224M -0.00392M 0.00500M 0.00500M
Change to liabilities -0.10293M 0.01M 0.15M -0.35420M
Total cashflows from investing activities -0.00224M -0.00392M 0.00500M 0.00500M
Net borrowings - - 7.50M 7.50M
Total cash from financing activities 0.00000M 21.36M 7.46M 1.20M
Change to operating activities -0.02772M -0.07526M 0.00872M -0.00155M
Net income -4.17441M -6.83759M -0.91523M -0.35221M
Change in cash -4.05883M 17.69M 6.62M 0.55M
Begin period cash flow 25.46M 7.76M - -
End period cash flow 21.40M 25.46M 7.76M -
Total cash from operating activities -4.25546M -3.96615M -0.85289M -0.64998M
Issuance of capital stock - 22.00M - -
Depreciation 0.00265M 0.00171M 0.00171M 0.00171M
Other cashflows from investing activities - 0.00000M 0.00500M -
Dividends paid - - - -
Change to inventory -0.02029M -0.02029M -0.02029M -0.02029M
Change to account receivables -0.45203M 0.00616M -0.17336M 0.04M
Sale purchase of stock 0.00000M -0.63884M 0.00000M 1.20M
Other cashflows from financing activities 0.00000M -0.00392M -0.03507M -0.03507M
Change to netincome 0.52M 2.93M 0.07M 0.02M
Capital expenditures 0.00224M 0.00392M 0.00392M 0.00392M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 0.42M 0.01M 0.00118M 0.00016M
Stock based compensation - - - -
Other non cash items - - - -
Free cash flow -4.25770M -0.00392M - -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TRP
Tissue Repair Ltd		 - -% 0.27 - - 8.61 0.85 46.90 1.96
CSL
CSL Ltd		 -3.45 1.22% 278.79 32.86 33.00 9.11 5.02 6.65 20.64
TLX
Telix Pharmaceuticals Ltd		 -0.07 0.27% 25.67 161.73 75.19 12.58 19.98 12.52 109.28
MSB
Mesoblast Ltd		 1.07 54.04% 3.05 - 454.55 312.43 2.49 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.36 2.79% 12.54 13.51 35.21 8.91 5.13 6.48 8.45

Reports Covered

Stock Research & News

View All

Profile

Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures. The company was incorporated in 2012 and is based in Chatswood, Australia.

Tissue Repair Ltd

Tower A, Level 9, Chatswood, NSW, Australia, 2067

Key Executives

Name Title Year Born
Mr. Tony Charara Co-Founder & Exec. Director NA
Mr. Cameron Jones C.A. Chief Financial Officer NA
Dr. Darryl Reed Chief Operating Officer NA
Mr. Michael Austin Company Sec. NA
Ms. Priyamvada Sanjay Rasal Company Secretary NA
Mr. Tony Charara Co-Founder & Executive Director NA
Mr. Tony Charara Co-Founder & Executive Director NA
Mr. Tony Charara Co-Founder & Executive Director NA
Ms. Priyamvada Sanjay Rasal Company Secretary NA
Mr. Tony Charara Co-Founder & Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.